



# NIDA: HIV, Drug Abuse, & You

**ROGER SORENSEN**  
**WOODY LIN**

INTEGRATIVE NEUROSCIENCE BRANCH  
DIVISION OF NEUROSCIENCE AND BEHAVIOR  
NIDA



# NIDA AIDS RESEARCH PROGRAM [ARP]

## Redonna Chandler, Director

- ▶ NIDA's **AIDS Research Program (ARP)** supports the development, planning, and coordination of high priority research on HIV/AIDS and drug abuse.

<https://www.drugabuse.gov/about-nida/organization/offices/aids-research-program-arp>

- ▶ **HIV/AIDS Program Contacts**

- ▶ NIDA's HIV/AIDS research grants are assigned to the Divisions within NIDA.

<https://www.drugabuse.gov/offices/office-nida-director-od/aids-research-program-arp/hivaids-program-contacts>

# NIDA BUDGET

(Thousands)

	FY 2015 Actuals	FY 2016 Operating Plan	FY 2017 PB	FY 2017 Senate Markup
NonAIDS	\$716,833	\$756,306	\$756,306	
AIDS	\$298,862	\$294,244	\$294,244	
TOTAL	\$1,015,695	\$1,050,550	\$1,050,550	\$1,103,032

**28% supports HIV/AIDS research**



# NIDA FOAs

## ONGOING

- ▶ [RFA-DA-18-019 \(DP1\)](#): NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (Clinical Trial Optional)
  - ▶ Aug 14 2018/2019/2020
  - ▶ does not require a detailed research plan
- ▶ [RFA-DA-18-004 \(DP2\)](#): Avenir Award Program for Research on Substance Abuse and HIV/AIDS
  - ▶ Nov 13 2018/2019; focuses on support for early stage investigators [NI/ESI]
  - ▶ does not require a detailed research plan
- ▶ [RFA-DA-18-022 \(R01\)](#): Advancing Exceptional Research on HIV/AIDS and Substance Abuse (Clinical Trial Optional)
  - ▶ Aug 22 2018/2019/2020;
  - ▶ required to have a detailed research plan and preliminary data.

Supports innovative research having the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, preventing disease transmission and improving disease outcomes, and eradicating HIV.

# NIDA FOAs

## ONGOING

- ▶ [PAS-18-063 \(R01\)](#): HIV/AIDS High Priority Drug Abuse Research (Clinical Trial Optional)
  - ▶ stimulate high priority research relevant to drug abuse and HIV/AIDS:
    - ▶ optimization of the seek, test, treat, and retain (STTR) paradigm
    - ▶ Implementation science research to prevent incidence and transmission
    - ▶ prevention
    - ▶ Criminal justice populations
    - ▶ Comorbidities and co-infections
    - ▶ Latency, reservoir size and persistence
- ▶ [PA-18-072 \(R03\)](#): AIDS-Science Track Award for Research Transition [A/START] (Clinical Trial Optional)
  - ▶ Support the entry of new investigators into research on drug abuse and HIV

# NIDA FOAs

## ONGOING

- ▶ [RFA-DA-18-023 \(R01\)](#): Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (Clinical Trial Not Allowed)
  - ▶ April 17 2018
  - ▶ support research that will define and validate a set(s) of molecular biomarkers and/or bio-signatures indicating the degree of loss of functional reserve, or of resilience of the host defense mechanisms, at different phases of HIV-1 pathogenesis in individuals with substance use disorders (SUDs).
- ▶ [RFA-DA-19-003 \(R61/R33\)](#): Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (Clinical Trial Optional)
  - ▶ July 17 2018/2019/2020
  - ▶ support Omics studies (e.g. transcriptomic, epigenomic, epitranscriptomic, proteomic, metabolomic, nucleomic, high throughput imaging or functional testing, etc.) to address outstanding questions regarding HIV latency or reservoirs in the context of chronic substance use or SUD.



# NIDA FOAs

## ONGOING

- ▶ [RFA-DA-19-004 \(U24\)](#): Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (Clinical Trial Not Allowed)
  - ▶ Aug 15 2018
  - ▶ fund a single interdisciplinary Coordinating Center to formalize and centralize support of the rural opioid initiative administered by NIDA and co-funded by CDC, SAMHSA, and ARC.
- ▶ [PA-18-071 \(R34\)](#): Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (Clinical Trial Optional)
  - ▶ *HIV Prevention, Treatment and Adherence Research, Program Implementation and Health Services Research*

# **NEW:** NIDA Topic Areas

- ▶ NIDA will reduce the number of PAs
  - ▶ NOT-DA-17-065
- ▶ Research areas of interest on NIDA website:
  - ▶ **Topic DAT18-01:** *[Title] [activity code(s)]*
  - ▶ **Provides:** purpose, background, NIDA contacts
- ▶ Application submitted thru other FOA
  - ▶ E.g. Parent FOAs



# NIDA FOAs

## PREVIOUSLY ISSUED

- ▶ [RFA-DA-18-015 \(R01\)](#): HIV-associated neuropathic pain and opioid interaction
- ▶ [RFA-DA-17-020 \(R01\)](#): Nicotinic Immune Modulation in the Presence of HIV-1 Infection
- ▶ [RFA-DA-18-014 \(R01\)](#): Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs
- ▶ [RFA-DA-18-016 \(R61/R33\)](#): Exploiting HIV and/or Host Genomic Information to Understand HIV Compartments or Reactivation in Individuals with Substance Use Disorders
- ▶ [RFA-DA-18-008 \(R01\)](#), [RFA-DA-18-009 \(R21\)](#): Exploring Novel RNA Modifications in HIV/AIDS and Substance Use Disorders
- ▶ [RFA-DA-18-011 \(U01\)](#): Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse
- ▶ [RFA-DA-17-024 \(R01\)](#): Optimizing the HIV Care Continuum for Substance Abusing Populations at High-Risk and/or Living with HIV

# NIDA FOAs

## FUTURE DIRECTIONS

### Opioids

#### Etiology & Pathogenesis

- ▶ Structural & Functional Changes in Chronic Disease
- ▶ Animal models
- ▶ Human imaging
- ▶ Neural circuitry and connectivity
- ▶ Glial Biology
- ▶ Disrupted physiological homeostasis [neurobiology, immune]

#### Prevention & Treatment

- ▶ Biomarkers

#### Neurological Complications

- ▶ HAND
- ▶ Addiction
- ▶ Neuropathic pain, re. abuse liability
- ▶ Cognition [executive function]